Can Weight-Loss Momentum Lift Hims & Hers Stock Before Q2 Earnings?
HIMS' second-quarter 2026 results are likely to benefit from weight-loss demand and global expansion even as margin pressures and higher spending linger.
Zacks
INSP Raises 2026 Outlook as Reimbursement Headwinds Start to Ease
Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.
Zacks
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.
Zacks
INSP's 28.1% Past-Month Rally Raises a Key Question for Investors
Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.
Zacks
Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.
Zacks
Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results
Inspire Medical Q2 Returns To Profit, Raises FY26 Outlook
(RTTNews) - Inspire Medical Systems, Inc. (INSP) on Monday reported a return to profitability in the second quarter...
Nasdaq News: Markets
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics
The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.